Government went under the brake for using Avastin with the indication for macular degeneration treatment
As Avastin was switched to drug with insurance reimbursement with the indication for metastatic colorectal cancer in March of this year, government went under the brake for using Avastin with the indication for macular degeneration treatment.
It was known that at the end of last month, National ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
